PDF(Pubmed)
Abstract：
Lipid disorders, primarily hypercholesterolemia, are the most common cardiovascular (CV) risk factor in Poland (this applies even 3/4 of people). The low-density lipoprotein cholesterol (LDL-C) serum level is the basic lipid parameter that should be measured to determine CV risk and determines the aim and target of lipid-lowering treatment (LLT). Lipid-lowering treatment improves cardiovascular prognosis and prolongs life in both primary and secondary cardiovascular prevention. Despite the availability of effective lipid-lowering drugs and solid data on their beneficial effects, the level of LDL-C control is highly insufficient. This is related, among other things, to physician inertia and patients\' fear of side effects. The development of lipidology has made drugs available with a good safety profile and enabling personalisation of therapy. Pitavastatin, the third most potent lipid-lowering statin, is characterised by a lower risk of muscle complications and new cases of diabetes due to its being metabolised differently. Thus, pitavastatin is a very good therapeutic option in patients at high risk of diabetes or with existing diabetes, and in patients at cardiovascular risk. This expert opinion paper attempts at recommendation on the place and possibility of using pitavastatin in the treatment of lipid disorders.
摘要：
脂质紊乱,主要是高胆固醇血症，是波兰最常见的心血管（CV）危险因素（这甚至适用于3/4的人）。低密度脂蛋白胆固醇（LDL-C）血清水平是确定CV风险并确定降脂治疗（LLT）目标的基本脂质参数。降脂治疗可改善心血管预后，并在一级和二级心血管预防中延长寿命。尽管有有效的降脂药物和有关其有益作用的可靠数据，LDL-C控制水平严重不足.这是相关的,除其他外，医生的惰性和患者对副作用的恐惧。血脂学的发展使药物具有良好的安全性并使治疗个性化。匹伐他汀,第三有效的降脂他汀类药物，其特点是肌肉并发症和新的糖尿病病例的风险较低，因为它的代谢不同。因此，匹伐他汀对于糖尿病高危患者或现有糖尿病患者是非常好的治疗选择，以及有心血管风险的患者。这份专家意见文件试图就使用匹伐他汀治疗脂质紊乱的地方和可能性提出建议。
